Impel Pharmaceuticals (FRA:84P) Debt-to-Equity : -1.25 (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Impel Pharmaceuticals Debt-to-Equity?

Impel Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was €105.47 Mil. Impel Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was €2.09 Mil. Impel Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Sep. 2023 was €-86.12 Mil. Impel Pharmaceuticals's debt to equity for the quarter that ended in Sep. 2023 was -1.25.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Impel Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

FRA:84P' s Debt-to-Equity Range Over the Past 10 Years
Min: -2.26 Med: -0.09 Max: 12.86
Current: -1.25

During the past 4 years, the highest Debt-to-Equity Ratio of Impel Pharmaceuticals was 12.86. The lowest was -2.26. And the median was -0.09.

FRA:84P's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs FRA:84P: -1.25

Impel Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Impel Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Impel Pharmaceuticals Debt-to-Equity Chart

Impel Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

-0.06

0.56

-1.16

Impel Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Debt-to-Equity	Get a 7-Day Free Trial											-2.26	-1.16	-0.73	-0.66	-1.25

Competitive Comparison of Impel Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, Impel Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Impel Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Impel Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Impel Pharmaceuticals's Debt-to-Equity falls into.

Impel Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Impel Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.455	+	46.865)	/	-41.684
	=	-1.16

Impel Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(105.472	+	2.094)	/	-86.115
	=	-1.25

Impel Pharmaceuticals (FRA:84P) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Impel Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Impel Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Impel Pharmaceuticals (FRA:84P) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Impel Pharmaceuticals Inc (FRA:84P) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

IMPLQ:USA

Address

201 Elliott Avenue West, Suite 260, Seattle, WA, USA, 98119

Website

https://www.impelpharma.com

Impel Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system. The company is developing an approach to drug delivery that administers specific formulations of drugs deep into the vascular-rich upper nasal space, a gateway for therapeutic administration of a versatile range of molecules and formulations.

Impel Pharmaceuticals (FRA:84P) Headlines

No Headlines